30-Second Takeaway
- ctDNA- and biomarker-guided strategies are beginning to translate into survival gains and refined treatment intensity.
- Checkpoint inhibitor combinations are redefining standards in recurrent/metastatic cervical, rectal, and biomarker-selected pancreatic cancers.
- Next-generation KRAS G12C inhibition shows pan-tumor potential, including post–KRAS inhibitor and CNS-active settings.
Week ending March 14, 2026
Biomarker-guided and intensified systemic strategies reshaping solid tumor management
ctDNA-guided risk-adaptive therapy improves outcomes in nasopharyngeal carcinoma
The multicenter phase II EP-STAR trial tested ctDNA-driven, risk-adapted therapy in nasopharyngeal carcinoma after gemcitabine–cisplatin neoadjuvant chemotherapy. Patients with risk-adaptive treatment achieved a 3-year failure-free survival of 89.1%. Compared with a contemporaneous external no–risk-adaptive cohort, failure-free survival significantly improved (HR 0.41; p = 0.004). The strategy was well tolerated, with no treatment-related deaths. These results support using on-treatment ctDNA dynamics to individualize escalation or de-escalation beyond fixed-course chemoradiotherapy.
Trilaciclib attenuates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesis
Across four randomized trials, trilaciclib with chemotherapy mitigated expansion of clonal hematopoiesis harboring DNA damage response mutations, including TP53. A syngeneic mouse model with TP53-mutant clonal hematopoiesis showed CDK4/6 inhibition blocked platinum-induced TP53-mutant competitive repopulation. Mechanistically, trilaciclib promoted hematopoietic stem and progenitor cell quiescence and reduced the stemness advantage of TP53-mutant clones. These data provide proof of concept that CDK4/6 inhibition can pharmacologically limit chemotherapy-driven expansion of preleukemic TP53-mutant clones.
TARGET-TP: biomarker-guided enoxaparin improves early survival in high–VTE-risk cancer
TARGET-TP randomized high-risk lung or gastrointestinal cancer patients, identified by a d-dimer/fibrinogen model, to enoxaparin prophylaxis versus no thromboprophylaxis. Thromboprophylaxis reduced thromboembolism and 6‑month mortality, with overall survival benefits persisting at 6 and 12 months. By 36 months, overall survival curves converged and no progression-free survival differences emerged. Adjustment for on-study thrombosis attenuated the survival effect, implicating reduced fatal thromboembolism as the primary driver. These findings support biomarker-guided, time-limited enoxaparin prophylaxis in selected high-risk lung and gastrointestinal cancer patients.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.